|Bid||6.04 x 1200|
|Ask||6.05 x 900|
|Day's Range||5.98 - 6.16|
|52 Week Range||5.72 - 51.60|
|Beta (3Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the
Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Gaithersburg, Maryland-based company said it had a loss of 11 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...
So close, and yet so far. That sums up the state of the markets recently, with investors jittery over the sudden chill surrounding U.S.-China relations. In an about-face on the trade dispute, President Trump conceded that tariffs on Chinese goods may remain for a "substantial period of time." Simultaneously, this hurts the broader markets but it also raises prospects for cheap stocks.I know what you're thinking: why should I consider cheap stocks to buy when blue-chip names are also available for deeply discounted prices? Far be it from me to disagree with that logic. Typically, you accrue the biggest profits from striking while others are panicking. But after you're comfortable with your high-probability bets, penny stocks provide exceptionally robust return potential.We should also discuss the "under-the-radar" argument. News such as the trade-war dispute disproportionately hurt the blue chips because they're usually multinational corporations with global vulnerabilities. While penny stocks also suffer the trickle-down effect, they're more likely to move on sector-specific developments.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs to Buy in the Second Quarter With that in mind, let's take a look at three (very) cheap stocks to buy that are worth every penny: Entree Resources (EGI)Source: Jeremy Vohwinkle via Flickr (Modified)Entree Resources (NYSEAMERICAN:EGI) is one of the penny stocks that actually benefits from broader and sector-specific trends. With all eyes focused on the suddenly deteriorating trade-war dispute, investors get nervous. When investors get nervous, they buy gold. Naturally, as a gold miner, EGI has a lot to gain.Another thing that intrigued me about EGI as a candidate for cheap stocks to buy is its locality. Most speculative miners have projects in extremely unstable countries just begging for nationalization. While Entree's main property in Mongolia isn't the greatest region for stability, it's also not the worst. Over the last few years, Mongolia improved its standing for ease of doing business.Additionally, the gold price has also improved, gaining roughly 10% since the first of October. That's a net positive for EGI stock, especially since it might go higher still. However, keep in mind that gold is extremely volatile, so don't lever yourself excessively. Genius Brands International (GNUS)Source: Shutterstock The entertainment industry is a tough sector in which to survive, let alone thrive. What works and what doesn't often seem arbitrary. Moreover, maintaining relevance is a gargantuan task once you've accomplished the already difficult task of delivering a hit. But the prospect of finding that hit drives Genius Brands International (NASDAQ:GNUS).GNUS specializes in creating compelling content and characters. Where it differs compared to other cheap stocks in the entertainment field is the company's core audience: toddlers to tweens. This is an exceptionally challenging market to crack because you're dealing with two audiences: the young consumer and their parents/guardians. * 10 Stocks on the Rise Heading Into the Second Quarter At the same time, GNUS has a viable pathway to profound growth. The reason? Brands such as cartoon characters translate very well internationally. If it resonates in America, it will probably resonate everywhere else. Novavax (NVAX)Source: Shutterstock Over the past few years, vaccination captured the public's attention, and not always in a good way. With President Trump's election, an increasing number of people became aware of so-called alternative-truth movements. Many of these right-leaning organizations rally fiercely against vaccination, particularly government-imposed protocols.On the surface, that doesn't help Novavax (NASDAQ:NVAX), which specializes in the stuff. Nor does the fact that NVAX is one of the riskiest penny stocks to buy. Since Feb. 27, shares have plummeted nearly 71%. Even more concerning is the reason why NVAX fell.In a clinical trial, the company's NanoFlu treatment failed to beat placebo. In other words, positive thinking yielded roughly the same efficacy in preventing influenza than the vaccine.Given that NVAX is a fundamentally poor organization, I'm not surprised that shares fell. However, keep in mind that most Americans support vaccination. Therefore, the broader financial incentive to stay the course until efficacy improves is incredibly high.As of this writing, Josh Enomoto is long gold. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post 3 Cheap Stocks to Buy That Are Worth Every Penny appeared first on InvestorPlace.